Astria Therapeutics reports Q1 EPS (38c), consensus (36c)

“We are thrilled with the ALPHA-STAR initial proof-of-concept results that we shared in March, and believe that STAR-0215 can be a life-changing therapy for people living with HAE,” said Jill C. Milne, Ph.D., Chief Executive Officer at Astria Therapeutics. “The efficacy we have seen to date, along with the favorable safety and tolerability profile with no injection pain observed, support the ability to administer STAR-0215 every three and every six months and give us confidence that we are developing a therapy that has the potential to lead the HAE market. We are progressing to a pivotal Phase 3 trial, expected to initiate in Q1 2025 for our Q3M regimen. Our plans are to develop a Q3M regimen first to take the fastest path to market, and then to rapidly expand the label with Q6M administration to further reduce the treatment burden for people with HAE.”